May 22, 2013 | By Márcio Barra
This Monday, It was confirmed that Actavis, the largest U.S. maker of generic drugs by market value, will acquire Ireland based, specialty pharmaceutical company Warner Chilcott in a stock-for-stock $8.5 billion deal, bigger than the previously reported $5 billion. This news comes after reports from last week that the two companies were in preliminary discussion.
Actavis CEO Paul Bisaro stated that the combined company “will be led by Actavis management”
This deal brings two new businesses to Actavis – gastroenterology and dermatology – and additional women health products, creating an $11 billion company.
pharmupdates.wordpress.com 